Esperion Therapeutics, Inc. (NASDAQ: ESPR) announced the initiation of the global cardiovascular outcomes trial (CVOT) to assess the effects of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE